Sunvozertinib Combined With Chemotherapy for EGFRm After EGFR-TKI Treatment Failure：Phase I/II

Inclusion Criteria

• •1. To provide a signed and dated, written informed consent.
• •2. 80≥Age ≥ 18 years old
• •3. Histologically or cytologically confirmed non-squamous NSCLC with documented EGFR mutations from a local laboratory
• •4. EGFR-sensitive mutations including exon 19 deletion and exon 21 L858R mutated, and exon 20 T790M mutated.
• •5. Predicted life expectancy ≥ 12 weeks
• •6. EGFR-TKI resistance or intolerant to standard EGFR TKIs therapy.
• •7. No previous systemic chemotherapy for advanced or metastatic disease.
• •8. Adequate organ system function:
• •9. Patient must have measurable disease according to RECIST 1.1.
• •10. Patients with stable or pre-treated brain metastasis (BM) can be enrolled